LYRA News
Archived Headlines
- US IPO Week Ahead: The IPO pipeline is active in a 1 IPO week 04/24/20
- US IPO Week Ahead: An empty calendar and a quiet week for the IPO market 04/09/20
- How the coronavirus has reshaped the 2020 IPO timeline 03/10/20
- US IPO Weekly Recap: GFL's billion-dollar IPO stumbles in shaky market 03/06/20
- Phase 2 ENT biotech Lyra Therapeutics files for a $58 million IPO 03/06/20
US IPO Weekly Recap: Biotech hot streak continues amid another wave of SPACs
Lyra Therapeutics (LYRA) popped 16% in its IPO this past week, the latest biotech to surge in its public debut. It was joined by three SPACs, continuing an uptick in blank check activity. Despite enduring ...read more
The IPO market’s slowest spring since the financial crisis
The 2020 IPO market saw its slowest March and April in over a decade, as volatility essentially shut the IPO window. Just seven IPOs priced during the past two months, a 70% decline from the 15-year average of 23 IPOs. ...read more
ENT biotech Lyra Therapeutics prices IPO at $16 high end
Lyra Therapeutics, a Phase 2 biotech developing an implantable drug-device for chronic rhinosinusitis, raised $56 million by offering 3.5 million shares at $16, the high end of the range of $14 to $16. Lyra Therapeutics plans to list on the Nasdaq under the...read more
ENT biotech Lyra Therapeutics sets terms for $53 million IPO
Lyra Therapeutics, a Phase 2 biotech developing an implantable drug matrix for chronic rhinosinusitis, announced terms for its IPO on Monday. The Watertown, MA-based company plans to raise $53 million by offering 3.5 million shares at a price range of $14...read more